140 related articles for article (PubMed ID: 26854449)
1. Essential oil of Cinnamon exerts anti-cancer activity against head and neck squamous cell carcinoma via attenuating epidermal growth factor receptor - tyrosine kinase.
Yang XQ; Zheng H; Ye Q; Li RY; Chen Y
J BUON; 2015; 20(6):1518-25. PubMed ID: 26854449
[TBL] [Abstract][Full Text] [Related]
2. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
5. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive and Therapeutic Efficacy of
Kubatka P; Kello M; Kajo K; Samec M; Jasek K; Vybohova D; Uramova S; Liskova A; Sadlonova V; Koklesova L; Murin R; Adamkov M; Smejkal K; Svajdlenka E; Solar P; Samuel SM; Kassayova M; Kwon TK; Zubor P; Pec M; Danko J; Büsselberg D; Mojzis J
Molecules; 2020 Mar; 25(6):. PubMed ID: 32204409
[TBL] [Abstract][Full Text] [Related]
8. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
10. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
11. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.
Beloueche-Babari M; Box C; Arunan V; Parkes HG; Valenti M; De Haven Brandon A; Jackson LE; Eccles SA; Leach MO
Br J Cancer; 2015 Mar; 112(7):1206-14. PubMed ID: 25742484
[TBL] [Abstract][Full Text] [Related]
14. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
15. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
[TBL] [Abstract][Full Text] [Related]
16. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.
Singh T; Gupta NA; Xu S; Prasad R; Velu SE; Katiyar SK
Oncotarget; 2015 Aug; 6(25):21268-82. PubMed ID: 26020804
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
[TBL] [Abstract][Full Text] [Related]
18. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
20. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA
Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
